Ultragenyx Pharmaceutical/$RARE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
Ticker
$RARE
Sector
Primary listing
Employees
1,371
Headquarters
Website
RARE Metrics
BasicAdvanced
$2.5bn
-
-$6.11
0.39
-
Price and volume
Market cap
$2.5bn
Beta
0.39
52-week high
$42.37
52-week low
$18.29
Average daily volume
1.7m
Financial strength
Current ratio
2.022
Quick ratio
1.652
Long term debt to equity
-492.576
Total debt to equity
-524.017
Interest coverage (TTM)
-7.70%
Profitability
EBITDA (TTM)
-497
Gross margin (TTM)
-31.49%
Net profit margin (TTM)
-90.90%
Operating margin (TTM)
-83.73%
Effective tax rate (TTM)
-0.66%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-25.45%
Return on equity (TTM)
1,566.48%
Valuation
Price to revenue (TTM)
3.719
Price to book
-10.38
Price to tangible book (TTM)
-5.4
Price to free cash flow (TTM)
-4.905
Free cash flow yield (TTM)
-20.39%
Free cash flow per share (TTM)
-5.097
Growth
Revenue change (TTM)
13.53%
Earnings per share change (TTM)
4.00%
3-year revenue growth (CAGR)
20.40%
3-year earnings per share growth (CAGR)
-15.85%
10-year earnings per share growth (CAGR)
2.76%
What the Analysts think about RARE
Analyst ratings (Buy, Hold, Sell) for Ultragenyx Pharmaceutical stock.
RARE Financial Performance
Revenues and expenses
RARE Earnings Performance
Company profitability
RARE News
AllArticlesVideos
Rare disease families find roadmap to drug development at bootcamps
CNBC·1 week ago
There's a New Rare-Earth Stock. Here's What Makes It Stand Out.
Barrons·2 weeks ago
RARE CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
Newsfile Corp·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ultragenyx Pharmaceutical stock?
Ultragenyx Pharmaceutical (RARE) has a market cap of $2.5B as of May 17, 2026.
What is the P/E ratio for Ultragenyx Pharmaceutical stock?
The price to earnings (P/E) ratio for Ultragenyx Pharmaceutical (RARE) stock is 0 as of May 17, 2026.
Does Ultragenyx Pharmaceutical stock pay dividends?
No, Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders as of May 17, 2026.
When is the next Ultragenyx Pharmaceutical dividend payment date?
Ultragenyx Pharmaceutical (RARE) stock does not pay dividends to its shareholders.
What is the beta indicator for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.